GLP-1 analogs reduced alcohol and nicotine use in animal studies by modifying brain reward pathways, with early clinical trials showing initial promise for human addiction treatment.
New addiction treatment classGLP-1 analogs could be the first major new pharmacological approach to substance use disorders in decades
What the researchers found
GLP-1 analogs have demonstrated the ability to reduce substance use in preclinical studies, decreasing alcohol and nicotine consumption in rodents and non-human primates by modifying neurotransmitter activity in brain reward pathways. These medications also showed neuroprotective effects, reducing the oxidative stress and neuroinflammation caused by chronic substance use.
Early clinical trials are beginning to show promise for translating these preclinical findings to humans, though evidence remains preliminary. The review highlights that GLP-1 analogs could address a major unmet need, given the limited success of existing pharmacotherapies for alcohol use disorder and the overall lack of effective treatments for substance use disorders.
Why it matters
Addiction treatment has extremely limited pharmacological options — only three drugs are approved for alcohol use disorder, and success rates are low. If GLP-1 analogs can reduce addictive behaviors through their effects on brain reward circuits, they could represent the first major new class of addiction medications in decades, repurposed from an already widely prescribed drug class.
The numbers in context
Reviewed preclinical + early clinical studies · Reduced alcohol and nicotine use in animal models · Neuroprotective effects demonstrated · Limited existing AUD pharmacotherapy options
How the study worked
Literature review searching PubMed and Cochrane databases for preclinical and early clinical studies on GLP-1 analogs and addiction, using keywords including 'GLP-1 analogs,' 'addiction,' and 'substance use disorders.'
Who was studied
Not applicable (literature review covering rodent, non-human primate, and early human studies)
What this study cannot tell us
Most evidence is preclinical (animal studies). Early clinical trials are few and small. Long-term adverse effects of GLP-1 analogs for addiction treatment are not yet understood. The review is narrative rather than systematic, and specific study quality assessments are not described.
How to read the evidence
This is a narrative literature review synthesizing mostly preclinical evidence with limited early clinical data. While the biological rationale is compelling, the evidence base for human addiction treatment remains preliminary.
When this study was published
Published in 2026, this review captures the most current research on GLP-1 drugs and addiction, a rapidly emerging field that has accelerated since widespread semaglutide use began revealing unexpected behavioral effects.
The bigger picture
The potential of GLP-1 drugs for addiction is one of the most exciting unexpected findings in modern pharmacology. Anecdotal reports from patients on semaglutide reporting reduced alcohol cravings sparked formal research, and this review summarizes the scientific basis — GLP-1 receptors are present in brain reward circuits, and activating them appears to dampen the reinforcing effects of addictive substances. Large clinical trials are now underway.
Questions still open
- Which specific GLP-1 analog (semaglutide, liraglutide, tirzepatide) is most effective for addiction?
- Do the anti-addiction effects persist after discontinuing GLP-1 therapy, or do cravings return?
- Could GLP-1 drugs help with addictions beyond alcohol and nicotine, such as opioids or stimulants?
Common questions
Can semaglutide or other GLP-1 drugs help with alcohol addiction?
How might GLP-1 drugs reduce addictive behaviors?
Read the original research
Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review.
Substance use & addiction journal, 47(1), 271-278
Citation
Noemi Torres, Isabel; Barroso Alverde, Maria Jimena. (2026). Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review.. Substance use & addiction journal, 47(1), 271-278. https://doi.org/10.1177/29767342251351111